Stroke is the one cardiovascular area where a plasmalogen supplement has actually been given to a living animal and an outcome measured, rather than a lipid merely being observed in patients. That makes this literature more interesting than most, and it also makes it easier to overstate. The animal study gave the supplement for fourteen days before the stroke, which is a very different claim from treating one. Nothing here is medical advice, and stroke is a medical emergency: sudden weakness, speech difficulty or facial droop needs emergency services immediately, not research reading.
Key Takeaways
- In a transient middle cerebral artery occlusion mouse model, scallop-derived plasmalogen at 10 mg/kg/day for 14 days before occlusion and through 5 days of reperfusion significantly reduced infarct volume and improved motor deficits on corner and rotarod testing[1].
- The same study reported reduced 4-HNE and 8-OHdG, two oxidative damage markers, and reduced Iba-1, IL-1 beta and TNF-alpha, with the inflammatory markers at p below 0.01[1].
- In 460 consecutive transient ischaemic attack patients sampled within 24 hours of symptom onset, 37 (8%) had a recurrent stroke within 90 days. Seven lipid species separated the two groups, and exactly one was a plasmalogen: PE(P-18:0/18:2), proposed as a candidate biomarker[2].
- In 187 human carotid plaques, arachidonate-containing ether lipids correlated positively with more stable plaque profiles, and Mendelian randomisation supported a causal link between LPCAT3 expression and reduced ischaemic stroke risk[3].
- Spatial imaging of carotid plaques from 12 patients found ether lipid metabolism enriched specifically in the collagen-rich regions of the lesion, not uniformly across it[4].
- No human has been given a plasmalogen supplement in a stroke trial, for prevention or treatment.
The Mouse Study, Read Carefully
A 2021 study used transient middle cerebral artery occlusion, the standard rodent model of ischaemic stroke. Adult male mice were pretreated with vehicle or scallop-derived plasmalogen at 10 mg/kg/day for 14 days, then subjected to 60 minutes of occlusion, then treated again through reperfusion and for five further days. Against vehicle, the plasmalogen group showed improved motor function on corner and rotarod tests, higher serum antioxidative capacity on OXY-adsorbent and d-ROMs testing, smaller infarction volume, lower expression of the oxidative stress markers 4-HNE and 8-OHdG, lower pro-inflammatory Iba-1, IL-1 beta and TNF-alpha, and less neurovascular unit damage measured by collagen IV, MMP9 and GFAP[1]. The authors describe it as the first demonstration of neuroprotection by scallop plasmalogen in acute ischaemic stroke.
Four things constrain what that result means. It is a 14-day pretreatment design, so it tests whether having elevated plasmalogen exposure before an insult helps, which is a prevention question, not a treatment one. It is male mice only. The dose is 10 mg/kg/day in a mouse, and mouse-to-human dose conversion is not a simple multiplication, so it does not translate into a capsule count. And the model produces a clean, timed, reperfused occlusion that human strokes rarely resemble.
It is still the strongest single piece of evidence in this section, because it is the only one where someone gave the substance and measured what happened. Readers weighing the marine-source question will find the comparison on our page about scallop-derived versus synthetic plasmalogens relevant here, since this study used the scallop form specifically.
The Human Data Is Observational, And Thin
The largest human dataset comes from transient ischaemic attack, the warning event that precedes many strokes. Untargeted lipidomics was run on plasma from 460 consecutive TIA patients recruited within 24 hours of symptom onset. Thirty-seven of them, 8%, had a recurrent stroke within 90 days. Seven lipid species were differentially expressed between recurrers and non-recurrers: five triacylglycerides, one diacylglyceride, and one alkenyl-phosphatidylethanolamine, PE(P-18:0/18:2), which is a plasmalogen. The authors proposed that species as a candidate biomarker of recurrence risk[2].
One species out of seven, in one cohort, with no replication reported. The authors’ own framing points at lipid droplet metabolism and antioxidant response as the underlying pathways rather than at plasmalogens as such. Treating this as evidence that plasmalogen status predicts stroke would be reading far past what a single differential-expression list supports.
The plaque work is more recent and more mechanistic. A 2025 study inactivated ELOVL5 and LPCAT3 in macrophages, two enzymes that between them elongate long-chain polyunsaturated fatty acids and incorporate them into phospholipids. Losing both promoted cholesterol-enriched membrane domains, made the macrophages more sensitive to cytotoxic oxysterols, and produced more vulnerable atherosclerotic plaques with enlarged necrotic cores in mice. In 187 human carotid plaques, the phospholipids generated by those enzymes, including arachidonate-containing ether lipids, correlated positively with more stable plaque profiles, and Mendelian randomisation supported a causal relationship between LPCAT3 expression and reduced ischaemic stroke risk[3].
That is a genuine causal inference, but note what it is about. The causal arrow runs from an enzyme’s expression level to stroke risk, not from a dietary ether lipid to stroke risk. Nothing in it implies that swallowing plasmalogens reproduces the effect of upregulating LPCAT3 inside a plaque macrophage.
The fourth study is included for texture rather than support. Desorption electrospray ionisation mass spectrometry imaging of carotid plaques from 12 patients, staged histologically into preatheroma, atheroma, fibroatheroma and complicated lesion, found ether lipid metabolism enriched specifically in the collagen-rich regions of the plaque, while sphingolipid signalling and necroptosis pathways dominated the lipid-rich regions[4]. Twelve patients, and a mapping exercise rather than an outcome study, but it does say the ether lipid signal in a plaque is regional rather than uniform.
What Would Actually Settle This
A randomised trial in people at elevated stroke risk, with a plasmalogen supplement against placebo and recurrent stroke or infarct volume as the endpoint. That trial does not exist, and neither does a smaller one using a surrogate. The human clinical trials that do exist are almost entirely cognitive, as our clinical trial summary sets out, and none of them enrolled stroke patients or reported any cerebrovascular endpoint.
Meanwhile the modifiable risk factors for stroke, blood pressure above all, then atrial fibrillation, smoking, diabetes and cholesterol, have decades of randomised evidence behind them and treatments that measurably reduce events. Anyone reading this page because stroke risk is a live personal concern is better served by that conversation with a clinician than by anything on this site. The broader cardiovascular picture, including where plasmalogens sit in it, is covered on our cardiovascular health page.
Frequently Asked Questions
Has a plasmalogen supplement been tested in stroke?
In mice, not in people. Scallop-derived plasmalogen at 10 mg/kg/day given for 14 days before a transient middle cerebral artery occlusion and through reperfusion reduced infarct volume and improved motor deficits against vehicle. No human trial has given a plasmalogen supplement for stroke prevention or treatment.
Does the mouse stroke study show plasmalogens treat a stroke?
No. It was a pretreatment design: the animals received the supplement for 14 days before the occlusion, so it tests whether prior exposure protects, which is a prevention question. It also used male mice only, and a mouse dose of 10 mg/kg/day does not convert simply into a human dose.
Do plasmalogen levels predict stroke recurrence?
One study suggests a candidate. Among 460 transient ischaemic attack patients sampled within 24 hours, 37 had a recurrent stroke within 90 days, and one plasmalogen species, PE(P-18:0/18:2), was among seven lipids separating the groups. It was one species out of seven, in a single cohort, with no replication reported.
What is the link between ether lipids and atherosclerotic plaque?
In 187 human carotid plaques, arachidonate-containing ether lipids correlated with more stable plaque profiles, and Mendelian randomisation supported a causal link between LPCAT3 expression and reduced ischaemic stroke risk. That causal arrow runs from enzyme expression to risk, not from a dietary ether lipid to risk.
References
- Feng T, Hu X, Fukui Y, et al. Neuroprotective effects of Scallop-derived plasmalogen in a mouse model of ischemic stroke. Brain research (2021). PMID 33991494
- Purroy F, Ois A, Jove M, et al. Lipidomic signature of stroke recurrence after transient ischemic attack. Scientific reports (2023). PMID 37607967
- Jalil A, Pilot T, Bourgeois T, et al. Plasmalogen remodeling modulates macrophage response to cytotoxic oxysterols and atherosclerotic plaque vulnerability. Cell reports. Medicine (2025). PMID 40345182
- Li W, Luo J, Peng F, et al. Spatial metabolomics identifies lipid profiles of human carotid atherosclerosis. Atherosclerosis (2023). PMID 36459728
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
